Table 3.
Camrelizumab combined with apatinibhad vs sorafenib.
| Camriezumab combined with alpatinib | Sorafenib | |
|---|---|---|
| OS, months | 22.1 | 15.2 |
| PFS,months | 5.6 | 3.7 |
| ORR % | 25.4% | 5.9% |
| DCR % | 78.3% | 53.9% |
| ≥3 TRAE % | 80.9% | 52.4% |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.